SWOG clinical trial number

An Intergroup Phase II Clinical Trial for Adolescents and Young Adults with Untreated Acute Lymphoblastic Leukemia (ALL)

Abbreviated Title
Phase II Adolescent/Young Adult with Untreated ALL
Status Notes
Permanent Closure Effective 9/14/12

NCORP, Members, Medical Oncologists, Pathologists, Affiliates

Research committees



Cytosine Arabinoside Cyclophosphamide Dexamethasone Vincristine 6-Mercaptopurine 6-Thioguanine Allopurinol Daunomycin Doxorubicin Leucovorin Calcium Methotrexate Trimethoprim sulfa PEG-L-Asparaginase

Eligibility Criteria Expand/Collapse

Newly diagnosed ALL with B or T-precursor. Pts with Burkitt type leukemia not eligible. 16 to 29 years (inclusive). 0-2 performance status. Pts with Down Syndrome not eligible. No prior therapy for ALL except emergency therapy (corticosteroids or hydroxyurea) for blast cell crisis, superior vena cava dyndrome or renal failure due to leukemic infiltration of kidneys. Single-dose intrathecal cytarabine allowed. (Chemo must begin within 72 hours of dose). Prior steroid therapy allowed but must be documented.

Publication Information Expand/Collapse


The impact of early PEG-asparaginase discontinuation in young adults with ALL: A post hoc analysis of the C10403 study

I Aldoss;J Yin;A Wall;K Mrozek;M Liedtke;D Claxton;M Foster;F Appelbaum;H Erba;M Litzow;M Tallman;R Stone;A Advani;W Stock;S Luger Blood Advances Jan 24;7(2):196-204

PMid: PMID36269846 | PMC number: PMC9841239


Disparities in trial enrollment and outcomes of Hispanic adolescent and young adult acute lymphoblastic leukemia

L Muffly;J Yin;S Jacobson;A Wall;E Quiroz;A Advani;S Luger;M Tallman;M Litzow;M Foster;F Appelbaum;H Erba;R Larson;T Keegan;W Stock Blood Advances Jul 26;6(14):4085-4092

PMid: PMID35838753


Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia

A Advani;E Larsen;K Laumann;S Luger;M Liedtke;M Devidas;Z Chen;Z Chen;J Yen;M Foster;D Claxton;K Coffan;M Tallman;F Appelbaum;H Erba;H Erba;R Stone;S Hunger;J McNeer;M Loh;E Raetz;N Winick;W Carroll;R Larson;W Stock Blood Advances Jan 26;5(2):504-512. doi: 10.1182/bloodadvances.2020002439.

PMid: PMID33496745 | PMC number: PMC7839367

Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR

M Wieduwilt;W Stock;A Advani;S Luger;R Larson;M Tallman;F Appelbaum;M-J Zhang;K Bo-Subait;H-L Wang;V Bhatt;B Dholaria;M Eapen;M Hamadani;O Jamy;T Prestidge;M Pulsipher;D Ritchie;D Rizzieri;A Sharma;P Barba;B Sandmaier;M de Lima;P Kebriaei;M Litzow;W Saber;D Weisdorf Leukemia Jul;35(7):2076-2085

PMid: PMID33785862 | PMC number: PMC8257494

Enrollment Characteristics and Outcomes of Hispanic and Black AYA ALL Patients Enrolled on a U.S. Intergroup Clinical Trial: A Comparison of the CALGB 10403 (Alliance) Cohort with U.S. Population-Level Data

L Muffly;J Yin;S Jacobson;A Advani;S Luger;M Tallman;M Litzow;R Larson;T Keegan;W Stock American Society of Hematology (Dec 11-14, 2021, Atlanta, GA), oral, #337


A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403

W Stock;S Luger;A Advani;J Yin;R Harvey;C Mullighan;C Willman;N Fulton;K Laumann;M Malnassy;E Paietta;E Parker;S Geyer;K Mrozek;C Bloomfield;B Sanford;G Marcucci;M Liedtke;D Claxton;M Foster;J Bogart;J Grecula;F Appelbaum;H Erba;M Litzow;M Tallman;R Stone;R Larson Blood Apr 4;133(14):1548-1559

PMid: PMID30658992 | PMC number: PMC6450431


An inherited genetic variant in CEP72 promoter predisposes to vincristine-induced peripheral neuropathy in adults with acute lymphoblastic leukemia

W Stock;B Diouf;KR Crews;D Pei;C Cheng;K Laumann;S Mandrekar;S Luger;A Advani;RM Stone;RA Larson;WE Evans Clinical Pharmacology and Therapeutics 2017 Mar;101(3):391-395. Epub 2016 Nov 16.

PMid: PMID27618250 | PMC number: PMC5320866


Favorable outcomes for adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL): early results of US intergroup trial CALGB 10403 (Alliance)

W Stock;S Geyer;S Luger;A Advani;R Harvey;C Mullighan;C Willman;E August Parker;K Laumann;BL Sanford;G Marcucci;E Paietta;MS Tallman;FR Appelbaum;HP Erba;M Litzow;R Stone;RA Larson Blood 124(21):796;American Society for Hematology (December 6-9, 2014, San Francisco, CA), oral;


Frontline treatment of acute lymphoblastic leukemia (ALL) in older adolescents and young adults (AYA) using a pediatric regimen is feasible: toxicity results of the prospective US intergroup trial CALGB 10403 (Alliance)

A Advani;B Sanford;S Luger;M Devidas;E Larsen;M Liedtke;p Voorhees;M Foster;D Claxton;E Parker;K Coffan;W Carroll;N Winik;S Coutre;M Tallman;F Appelbaum;H Erba;R Stone;S Hunger;RA Larson;W Stock Blood 122:1443; American Society of Hematology annual meeting (Dec 7-10, 2013, New Orleans, LA), poster;


Who participates in an adult cooperative group trial for adolescent and young adults (AYAs)? Baseline demographic and psychosocial characteristics of AYAs enrolled on intergroup trial C10403 for acute lymphoblastic leukemia (ALL)

L Muffly;W Stock;A Breitenbach;S Mulkey;S Luger;A Advani;E Parker;MC Foster;M Liedtke;R Garcia;K Coffan;J Sipin-Sayno;J McNeer;M Tallman;F Appelbaum;R Stone;R Larson Blood 120(21):abst.3535; American Society of Hematology Annual Meeting, poster presentation


Older adolescents and young adults with acute lymphoblastic leukemia (ALL) in the United States: from the lowest to highest death rate and number of deaths -- more rationale for the CALBG-WSOG-ECOG C10403 trial based on COG AALL0232

WA Bleyer Journal of Clinical Oncology 26(15s):abstr. #18034